WO2013036567A2 - Methods, compositions, and compounds for the reduction of illegal methamphetamine production - Google Patents
Methods, compositions, and compounds for the reduction of illegal methamphetamine production Download PDFInfo
- Publication number
- WO2013036567A2 WO2013036567A2 PCT/US2012/053850 US2012053850W WO2013036567A2 WO 2013036567 A2 WO2013036567 A2 WO 2013036567A2 US 2012053850 W US2012053850 W US 2012053850W WO 2013036567 A2 WO2013036567 A2 WO 2013036567A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prodrug
- ephedrine
- isomers
- pseudoephedrine
- methamphetamine
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 80
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 title claims abstract description 54
- 229960001252 methamphetamine Drugs 0.000 title claims abstract description 54
- 150000001875 compounds Chemical class 0.000 title claims abstract description 35
- 230000009467 reduction Effects 0.000 title claims description 21
- 239000000203 mixture Substances 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims abstract description 154
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims abstract description 147
- 239000000651 prodrug Substances 0.000 claims abstract description 95
- 229940002612 prodrug Drugs 0.000 claims abstract description 95
- 229960002179 ephedrine Drugs 0.000 claims abstract description 77
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims abstract description 69
- 229960003908 pseudoephedrine Drugs 0.000 claims abstract description 69
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 13
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 150000002148 esters Chemical class 0.000 claims description 16
- 238000011084 recovery Methods 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 15
- 229910052740 iodine Inorganic materials 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 206010046543 Urinary incontinence Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 208000027744 congestion Diseases 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 208000005346 nocturnal enuresis Diseases 0.000 claims description 4
- 208000001953 Hypotension Diseases 0.000 claims description 3
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims description 3
- 230000036543 hypotension Effects 0.000 claims description 3
- 201000003631 narcolepsy Diseases 0.000 claims description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 2
- 238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- -1 phenylephrine Chemical class 0.000 description 67
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 33
- 125000001424 substituent group Chemical group 0.000 description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 19
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 17
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 16
- 238000006722 reduction reaction Methods 0.000 description 16
- 241000124008 Mammalia Species 0.000 description 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 150000004665 fatty acids Chemical class 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 125000001183 hydrocarbyl group Chemical group 0.000 description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 150000001263 acyl chlorides Chemical class 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 6
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 5
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000001743 benzylic group Chemical group 0.000 description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000007127 saponification reaction Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- 229930194542 Keto Natural products 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 229940025084 amphetamine Drugs 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 239000013626 chemical specie Substances 0.000 description 3
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 3
- 150000002373 hemiacetals Chemical class 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- 0 *OC(C=CC(Cl)=O)=O Chemical compound *OC(C=CC(Cl)=O)=O 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- QXKAIJAYHKCRRA-UHFFFAOYSA-N D-lyxonic acid Natural products OCC(O)C(O)C(O)C(O)=O QXKAIJAYHKCRRA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 235000021319 Palmitoleic acid Nutrition 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 2
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical class OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000010931 ester hydrolysis Methods 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 2
- 229960002733 gamolenic acid Drugs 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- KWGRBVOPPLSCSI-SCZZXKLOSA-N (1r,2r)-2-(methylamino)-1-phenylpropan-1-ol Chemical compound CN[C@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-SCZZXKLOSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- RGHNJXZEOKUKBD-TXICZTDVSA-N (2r,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-TXICZTDVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-STGXQOJASA-N (2s,3s,4s,5r)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)C(O)=O RGHNJXZEOKUKBD-STGXQOJASA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical class CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-AIHAYLRMSA-N D-altronic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O RGHNJXZEOKUKBD-AIHAYLRMSA-N 0.000 description 1
- QXKAIJAYHKCRRA-JJYYJPOSSA-N D-arabinonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(O)=O QXKAIJAYHKCRRA-JJYYJPOSSA-N 0.000 description 1
- JPIJQSOTBSSVTP-PWNYCUMCSA-N D-erythronic acid Chemical compound OC[C@@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-PWNYCUMCSA-N 0.000 description 1
- RGHNJXZEOKUKBD-MGCNEYSASA-N D-galactonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-MGCNEYSASA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- QXKAIJAYHKCRRA-UZBSEBFBSA-N D-lyxonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(O)=O QXKAIJAYHKCRRA-UZBSEBFBSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-MBMOQRBOSA-N D-mannonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O RGHNJXZEOKUKBD-MBMOQRBOSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- QXKAIJAYHKCRRA-BXXZVTAOSA-N D-ribonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O QXKAIJAYHKCRRA-BXXZVTAOSA-N 0.000 description 1
- JPIJQSOTBSSVTP-GBXIJSLDSA-N D-threonic acid Chemical compound OC[C@@H](O)[C@H](O)C(O)=O JPIJQSOTBSSVTP-GBXIJSLDSA-N 0.000 description 1
- QXKAIJAYHKCRRA-FLRLBIABSA-N D-xylonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(O)=O QXKAIJAYHKCRRA-FLRLBIABSA-N 0.000 description 1
- 235000016936 Dendrocalamus strictus Nutrition 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- RGHNJXZEOKUKBD-QTBDOELSSA-N L-gulonic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O RGHNJXZEOKUKBD-QTBDOELSSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SKNVOMKLSA-N L-idonic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SKNVOMKLSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 125000005631 S-sulfonamido group Chemical group 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical class OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000004986 diarylamino group Chemical group 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000002920 hazardous waste Substances 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000003104 hexanoyl group Chemical class O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- PKAHQJNJPDVTDP-UHFFFAOYSA-N methyl cyclopropanecarboxylate Chemical compound COC(=O)C1CC1 PKAHQJNJPDVTDP-UHFFFAOYSA-N 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- DCUJJWWUNKIJPH-UHFFFAOYSA-N nitrapyrin Chemical compound ClC1=CC=CC(C(Cl)(Cl)Cl)=N1 DCUJJWWUNKIJPH-UHFFFAOYSA-N 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003077 polyols Chemical group 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000005423 trihalomethanesulfonamido group Chemical group 0.000 description 1
- 125000005152 trihalomethanesulfonyl group Chemical group 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- Methamphetamine abuse is a growing problem. A large part of this problem stems from the ease of synthesis of methamphetamine from the common legitimate medications ephedrine and pseudoephedrine. These compounds are converted to methamphetamine by a reduction reaction that is so simple to carry out that anyone can do it. It is estimated that 99% of clandestine drug laboratories in the US are involved in methamphetamine manufacture.
- Ephedrine or pseudoephedrine is usually converted to methamphetamine by using either red phosphorous obtained from matches and iodine created in situ from HI (P/l method), or by the "Nazi method," which is a dissolving metal reduction that uses ammonia and lithium removed from batteries.
- the U.S. Drug Enforcement Agency (DEA) recognizes two classes of clandestine methamphetamine producers. The first class, called “super-labs,” are those capable of making 10 pounds or more of methamphetamine in a 24-hour period. These labs are operated by criminal organizations. The second class, called small toxic labs (STL), are those that are operated independently.
- the STLs obtain their ephedrine or pseudoephedrine by purchasing an over the counter dosage form at a store or on the internet and extracting the drug.
- the super-labs divert large amounts of the pseudoephedrine or ephedrine from legitimate uses. Although most labs are STLs, the super-labs actually produce a greater share of the methamphetamine being used in the US.
- Clandestine methamphetamine production is more than just a drug problem, it is a safety and environmental problem. Methamphetamine labs often explode or catch fire. Furthermore, according to the DEA, one pound of clandestine methamphetamine production yields 5-6 pounds of hazardous waste. In 2003, the cost to the DEA for cleanup of methamphetamine labs was $16 million.
- Preferred chemical reagents include Fe(lll)citrate, ferrocene, 2- chloro-6-(trichloromethyl)pyridine and 1 ,1 ,1 ,2-tetrafluoroethane.”
- this method is ineffective in reducing methamphetamine synthesis via the P/l method.
- pseudoephedrine is replaced in some products. But pseudoephedrine is still in demand because for many people, phenylephrine is significantly less effective in relieving congestion and other symptoms.
- Clandestine methamphetamine synthesis could be substantially curtailed by replacing the pseudoephedrine and ephedrine that is manufactured, transported, sold, stored, or administered to a mammal, including a human being, with prodrugs of the pseudoephedrine and ephedrine.
- pseudoephedrine or ephedrine would no longer be available for a criminal to steal or purchase for conversion to methamphetamine because it is replaced by the prodrug.
- the prodrug would be more difficult than pseudoephedrine and ephedrine to convert to methamphetamine, thus decreasing the availability of the drug and discouraging clandestine manufacture.
- pseudoephedrine includes manufacturing the prodrug in any situation where pseudoephrine or ephedrine might be manufactured for a similar purpose.
- the prodrug would be manufactured for use in treating a mammal, including a human being, where pseudoephedrine or ephedrine might be used to treat that mammal.
- Selling a prodrug of ephedrine or pseudoephedrine to replace ephedrine or pseudoephedrine includes selling the prodrug in any situation where pseudoephrine or ephedrine might also be sold for a similar purpose.
- the prodrug would be sold for use in treating a mammal, including a human being, where pseudoephedrine or ephedrine might be used to treat that mammal.
- pseudoephedrine includes transporting the prodrug in any situation where pseudoephrine or ephedrine might also be transported for a similar purpose.
- the prodrug would be transported to a location for use in treating a mammal, including a human being, where pseudoephedrine or ephedrine might be used to treat that mammal.
- Storing a prodrug of ephedrine or pseudoephedrine to replace ephedrine or pseudoephedrine includes storing the prodrug in any situation where pseudoephrine or ephedrine might also be stored for a similar purpose.
- the prodrug would be stored in a location for use in treating a mammal, including a human being, where pseudoephedrine or ephedrine might be used to treat that mammal.
- pseudoephedrine includes administering the prodrug in any situation where pseudoephrine or ephedrine might also be administered for a similar purpose.
- the prodrug would be administered to a mammal, including a human being, where pseudoephedrine or ephedrine might be administered to treat that mammal.
- the more ephedrine or pseudoephedrine that is replaced by a prodrug the more clandestine methamphetamine synthesis may be prevented.
- the ephedrine or pseudoephedrine replaced may be in a single composition or several different compositions, such as in a powder form; or in one or more units of at least one dosage form.
- some embodiments include a composition or several different compositions, or multiple units of a dosage form, comprising a prodrug of ephedrine or
- compositions, compositions, or dosage forms comprising the prodrug may be manufactured, sold, transported, or stored to replace ephedrine or pseudoephedrine.
- the amount of the prodrug may be at least about 1 g, about 100 g, about 1 kg, or about 10 kg, up to about 1 ,000 kg, about 10,000 kg, about 100,000 kg, or about 1 ,000,000 kg of a prodrug of ephedrine or pseudoephedrine
- Dosage forms may be provided for administration of the prodrug to a mammal, including a human being, such as a human being to treat a condition normally treated by ephedrine or pseudoephedrine.
- the dosage forms may comprise any therapeutically effective amount of the prodrug.
- the dosage form comprises at least about 0.00003 moles, about 0.00006 moles, about
- prodrug has the ordinary meaning known to one of ordinary skill in the art.
- a prodrug includes a compound which is converted to a therapeutically active compound after administration to a mammal such as a human being.
- conversion may occur by hydrolysis of an ester group or some other biologically labile group.
- Prodrug preparation is well known in the art. For example, “Prodrugs and Drug Delivery Systems,” which is a chapter in Richard B.
- the prodrug may comprise a derivative of the benzylic hydroxide of ephedrine or pseudoephedrine. In some embodiments, the prodrug may be an ester of the benzylic hydroxide of ephedrine or pseudoephedrine. In some embodiments, the prodrug may be a stable compound having one of the formulas: wherein X is a single bond, CO, C0 2) CON, S, P0 3 , S0 2 NH, CH 2 0, CH2OCO, or C2H4OCO2,
- R is H, or a moiety having from 0 to 30 carbon atoms, from 4 to 30 carbon atoms, or from 10 to 30 carbon atoms, and from 0 to 30 heteroatoms, 0 to 20 heteroatoms, 0 to 10 heteroatoms, or 0 to 5 heteroatoms selected from N, O, S, F, CI, I, Br, P, and combinations thereof, provided that at least 1 atom selected from C, N, O, or S is present.
- a chemical structural feature such as phenyl when referred to as being “optionally substituted,” it is meant that the feature may have no substituents (i.e. be unsubstituted) or may have one or more substituents.
- a feature that is "substituted” has one or more substituents.
- substituted has the ordinary meaning known to one of ordinary skill in the art.
- the substituent is an ordinary organic moiety known in the art, which may have a molecular weight (e.g.
- the substituent comprises: about 0-30, about 0-20, about 0-10, or about 0-5 carbon atoms; and about 0-30, about 0-20, about 0-10, or about 0-5 heteroatoms independently selected from: N, O, S, P, Si, F, CI, Br, I, and combinations thereof; provided that the substituent comprises at least one atom selected from: C, N, O, S, P, Si, F, CI, Br, and I.
- substituents include, but are not limited to, alkyl, alkenyl, alkynyl, carbazolyl, aryl, diarylamino, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, protected hydroxy, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O- carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfenyl,
- a stable compound includes a compound which is sufficiently stable to store under a normal atmosphere for at least 24 hours at room temperature.
- reference to a compound should be construed broadly to include pharmaceutically acceptable salts, tautomers, alternate solid forms, non-covalent complexes, and combinations thereof, of a chemical entity of the depicted structure or chemical name.
- a pharmaceutically acceptable salt includes any salt of the parent compound that is suitable for administration to an animal or human.
- a pharmaceutically acceptable salt also refers to any salt which may form in vivo as a result of administration of an acid, another salt, or a prodrug which is converted into an acid or salt.
- a salt comprises one or more ionic forms of the compound, such as a conjugate acid or base, associated with one or more corresponding counter-ions. Salts can form from or incorporate one or more deprotonated acidic groups (e.g. carboxylic acids), one or more protonated basic groups (e.g. amines), or both (e.g. zwitterions).
- Tautomers include isomers that are in rapid equilibrium with one another.
- tautomers may be related by transfer of a proton, hydrogen atom, or hydride ion.
- a structure is intended to include every possible stereoisomer, both pure or in any possible mixture.
- Alternate solid forms include different solid forms than those that may result from practicing the procedures described herein.
- alternate solid forms may be polymorphs, different kinds of amorphous solid forms, glasses, and the like.
- Non-covalent complexes include complexes that may form between the compound and one or more additional chemical species that do not involve a covalent bonding interaction between the compound and the additional chemical species. They may or may not have a specific ratio between the compound and the additional chemical species. Examples might include solvates, hydrates, charge transfer complexes, and the like.
- compounds may be prepared by combining the corresponding acyl chloride or carboxylic acid anhydride with ephedrine or pseudoephedrine, possibly in the presence of a base. They also may be prepared from an ester such as the methyl or ethyl ester by transesterification. These kinds of reactions are well known in the art. For example, see Smith and March, March's Organic Chemistry: Reactions, Mechanisms, and Structure, 5 th Ed., New York: John Wiley & Sons, Inc., pp. 482-492, and 523-524.
- a prodrug leaving group is the compound that would result if only the bond between pseudoephedrine and the remaining part of the molecule were hydrolyzed.
- the prodrug leaving group is RCO2H.
- R is hydrocarbyl having from 1 to 24 carbo i atoms.
- Hydrocarbyl includes compounds having only carbon and hydrogen.
- R is alkyl having from 1 to 12 carbon atoms, such as methyl (CH3); ethyl (C2H5); propyl isomers (C3H7) such as propyl, isopropyl, etc.; cyclopropyl, (C3H6); butyl isomers (C4H9); cyclobutyl isomers (C4H8) such as cyclobutyl, methylcyclopropyl, etc.; pentyl isomers (C5H11); cyclopentyl isomers (C5H10); hexyl isomers (C6H13); cyclohexyl isomers (C6H12); heptyl isomers (C7H13); cycloheptyl isomers (C7H14); octyl isomers (C8H17); cyclooctyl isomers (CeHi6); nonyl isomers (C9H17
- -X-R may be one of the moieties shown below:
- R a may be H; C1-12 alkyl such as methyl (CH3); ethyl (C2H5); propyl isomers (C3H7) such as propyl, isopropyl, etc.; cyclopropyl, (C3H6); butyl isomers (C4H9); cyclobutyl isomers (C4H8) such as cyclobutyl, methylcyclopropyl, etc.; pentyl isomers (C5H11); cyclopentyl isomers (C5H10); hexyl isomers (G6H13); cyclohexyl isomers (C6H12); heptyl isomers (C7H13); cycloheptyl isomers (C7H14); octyl isomers (CsHi 7 ); cyclooctyl isomers (CeHie); non
- R b may be H; C1-12 alkyl such as methyl (CH3); ethyl (C2H5); propyl isomers (C3H7) such as propyl, isopropyl, etc.; cyclopropyl, (C3H6); butyl isomers (C4H9); cyclobutyl isomers (C4H8) such as cyclobutyl, methylcyclopropyl, etc.; pentyl isomers (C5H11); cyclopentyl isomers (C5H10); hexyl isomers (C6H13); cyclohexyl isomers (C6H12); heptyl isomers (C7H13); cycloheptyl isomers (C7H14); octyl isomers (C8H17); cyclooctyl isomers (C 8 Hi6); nonyl isomers (CH3); ethyl (C
- R b may be H, CH 3 , CH2CH3, C(CH 3 ) 2 , C4H9, or unsubstituted phenyl.
- R c may be H; C1-12 alkyl such as methyl (CH3); ethyl (C2H5); propyl isomers (C3H7) such as propyl, isopropyl, etc.; cyclopropyl, (C3H6); butyl isomers (C 4 Hg); cyclobutyl isomers (C 4 H 8 ) such as cyclobutyl, methylcyclopropyl, etc.; pentyl isomers (C5H11); cyclopentyl isomers (C5H10); hexyl isomers (C6H13); cyclohexyl isomers (C6H12); heptyl isomers (C7H13); cycl
- R d may be H; C1-12 alkyl such as methyl (CH3); ethyl (C2H5); propyl isomers (C3H7) such as propyl, isopropyl, etc.; cyclopropyl, (C3H6); butyl isomers (C4Hg); cyclobutyl isomers (C4H8) such as cyclobutyl, methylcyclopropyl, etc.; pentyl isomers (C5H11); cyclopentyl isomers (C5H10); hexyl isomers (C6H13); cyclohexyl isomers (C6H12); heptyl isomers (C7H13); cycloheptyl isomers (C7H14); octyl isomers (C 8 Hi 7 ); cyclooctyl isomers (C 8 Hi6); non
- a may be 0, 1 , 3, 4, 5, or 6.
- a 1 may be a bond, CO, or C0 2 .
- a 2 may be O, S, or R a
- a 3 may be a bond, CO, or C0 2 .
- a 3 may be a bond, CO, or C0 2 .
- a 3 may be a bond, CO, or C0 2 .
- the prodrug leaving group, or RCO2H is a fatty acid.
- Fatty acids include linear carboxylic acids which have an even number of carbon atoms. Examples include, but are not limited to:
- unsaturated fatty acids including, but are not limited to, the following:
- Some fatty acids have 14 carbon atoms such as myristic acid.
- Some fatty acids have 16 carbon atoms such as palmitic and palmitoleic acid.
- Some fatty acids have 18 carbon atoms such as stearic acid, oleic acid, linoleic acid, a- linolenic a, and ⁇ -linolenic acid.
- Some fatty acids have 20 carbon atoms such as eicosapentaenoic acid.
- RCO2H is an amino acid, such as glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, asparagine, glutamine, tyrosine, cysteine, lysine, arginine, histidine, aspartic acid, glutamic acid, or a salt, ester, amide, carbonate or carbamate of an amino acid.
- amino acid such as glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, asparagine, glutamine, tyrosine, cysteine, lysine, arginine, histidine, aspartic acid, glutamic acid, or a salt, ester, amide, carbonate or carbamate of an amino acid.
- a moiety which further interferes with the reaction may be added.
- One such moiety is a ketone. Since iodine is formed in situ in the presence of acid in this method of amphetamine synthesis, the a-carbon of a ketone may react to form an a- iodoketone. Thus, this side reaction may further interfere with preparation of methamphetamine.
- Another moiety which may interfere with both the P/l method and the Vietnamese method is hydroxyl (-OH).
- benzylic hydroxyl may be especially problematic because of its similarity to the hydroxyl of ephedrine or pseudoephedrine to be reduced.
- Polyol moieties, such as those from sugars or other carbohydrates may also interfere with the reduction.
- Phenyl or aryi with an electronic withdrawing substituent may be particularly problematic for a clandestine manufacturer.
- R is has from 1 to 24 carbon atoms and from 1 to 24 oxygen atoms.
- An acetal moiety includes:
- R 1 and R 2 are independently hydrocarbyl.
- a hemiacetal moiety includes:
- R 1 is hydrocarbyl
- ketal moiety includes:
- R 1 and R 2 are independently hydrocarbyl.
- a hemiketal moiety includes
- R 1 is hydrocarbyl
- An ester moiety is -CO2-, where both the carbon and the saturated oxygen atom are directly attached to carbon atoms.
- R include: [a] hydroxymethyl substituted phenyl, such as hydroxymethylphenyl,
- alkyl such as methyl, ethyl, propyl isomers, butyl isomers, and the like;
- alkoxy such as methoxy, ethoxy, etc.
- amino such as NH2, NH-alkyl, N(alkyl)2, etc.
- the prodrug leaving group is a keto-acid or a polyketo-acid.
- the prodrug leaving group is a carboxylic acid that has one or more ketone functional groups.
- the prodrug may be modified to further interfere with methamphetamine synthesis by adding a moiety which is difficult to separate from ephedrine or pseudoephedrine during work-up of a saponification.
- a moiety which is difficult to separate from ephedrine or pseudoephedrine during work-up of a saponification.
- Part of the work up procedure of methamphetamine synthesis relies on protonating the amine to make the compound water soluble, washing out impurities, and then recovering the methamphetamine by deprotonating the amine.
- an amine moiety could further complicate the separation process.
- the combination of an amine with one or more hydroxyl moieties could provide an impurity upon saponification that is difficult to separate and interferes with the reduction.
- a prodrug which saponifies to form glucosamine would be useful.
- prodrugs may be prepared by reacting an acid chloride (Cl-X-R) with pseudoephedrine or ephedrine, as shown in Scheme A.
- a base may be used for some reactions to help remove HCI generated during the reaction.
- the hydrochloride salt of tne amine group may be reacted with the acid chloride.
- Dicarboxylic acid ester prodrugs may be prepared by reacting a dicarboxylic acid anhydride with pseudoephedrine or ephedrine.
- Scheme B illustrates an example that may be generalized to many other dicarboxylic acids.
- Some dicarboxylic acid diester prodrugs may be prepared by reaction with an acyl chloride ester.
- the acyl chloride ester may be prepared by reacting a dicarboxylic acid anhydride with an alcohol, followed by reaction with thionyl chloride or oxallyl chloride.
- Scheme C illustrates an example
- Some carbamate protected amino acid based ester prodrugs may be prepared by reacting the amino acid with excess phosgene, possibly in the presence of a base, followed by an alcohol such as R a OH. Reaction with water under mild conditions may free the carboxylic acids by hydrolysis, which may be converted to the acyl chloride using oxallyl chloride or another similar reagent. I his protected amino acid chloride may then be reacted with ephedrine or pseudoephedrine.
- Scheme D shoes an example that may be generalized to many compounds.
- Some amide protected amino acid based ester prodrugs may be prepared in a manner similar to the carbamates. Excess acyl chloride is reacted with the amino acids and the acid anhydrides are hydrolyzed. The resulting protected amino acids may be converted to the amino acid acyl chloride using oxallyl chloride or another similar reagent. This protected amino acid chloride may then be reacted with ephedrine or pseudoephedrine.
- Scheme E shoes an example that may be generalized to many compounds.
- Scheme E In any of schemes A-E, the amine of pseudoephedrine or ephedrine may be protected.
- the compound below may be used in place of pseudoephedrine or ephedrine to obtain an N- protected prodrug.
- One useful prodrug is depicted below. There are several ways it may be prepared. One method would to convert acetylsalicylic acid, i.e. aspirin, to the corresponding acyl chloride, and reacting with ephedrine or pseudoephedrine by methods known in the art, as shown in Scheme 1 below.
- Another useful prodrug is an ester of an aldonic acid, such as the compound depicted below.
- Examples include, but are not limited to: glyceronic acid, erythronic acid, threonic acid, ribonic acid, arabinonic acid, xylonic acid, lyxonic acid, allonic acid, altronic acid, gluconic acid, mannonic acid, gulonic acid, idonic acid, galactonic acid, talonic acid, and the like.
- These compounds may be prepared by a number of methods. For example, the hydroxyl groups of a sugar with a terminal aldehyde could be protected, the aldehyde could then be oxidized to a carboxylic acid, the acid converted to an anhydride or a acyl chloride, and the protecting groups removed, as shown in Scheme 2 below.
- sugar related acids such as those derived from disaccharides and polysaccharides having a terminal aldehyde, or an acetal or hemiacetal moiety that may be converted to a carboxylic acid.
- Other sugar related acids that might be used include uronic acids, such as glucuronic acid, glacturonic acid, mannuronic acid; ascorbic acid; ribose, deoxyribose, fucose, and the like.
- Sugar derivatives having other functionalities, such as amino sugars, might also be used in mine, is typical.
- Scheme 3 illustrates one method that might be used.
- the protected glucosamine is prepared as described in WO 03/022860.
- This compound is reacted with succinic anhydride to form the succinic acid ester shown.
- This is then converted to the acyl chloride and reacted with ephedrine or pseudoephedrine to give the protected product.
- the protected product is deprotected with ethylene diamine, followed by TFA or tosic acid as described in WO 03/022860.
- sugar-derived prodrugs may be further modified by addition of a phenyl moiety.
- benzoic acid could be added to one of the hydroxyl groups to form esters such as those shown below.
- the phenyl group may further interfere with methamphetamine synthesis, particularly by olving metal conditions.
- the prodrug leaving group comprises a phenyl ring comprising one or more substituents having a benzylic hydroxyl moiety and an amine moiety.
- the benzylic hydroxyl and the amine may be on the same substituent, or they may be on different substituents.
- the benzylic hydroxyl moiety may be in the form of an ester which is formed by a linker, such as a dicarboxylic acid ester linker, which connects to the benzylic oxygen of pseudoephedrine or ephedrine.
- some prodrugs may be compounds represented by one ot the fallowing formulas:
- the aryl or phenyl may have 0, 1 , 2, 3, or 4 substituents independently selected from: Ci-s alkyl, such as methyl, ethyl, propyl isomers, cyclopropyl, butyl isomers, cyclobutyl isomers (such as cyclobutyl, methylcyclopropyl, etc.), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; Ci-6 alkoxy, such as methoxy, ethoxy, propoxy isomers (e.g.
- Ci-s acyl such as formyl, acetyl, propionoyl butyryl, isobutyryl, cyclopropanecarbonyl, pentanoyl isomers (such as pentanoyl, methylbutanoyl, pivaloyl, etc.), cyclobutanecarbonyl isomers (such as methylcyclopropane carbonyl,
- cyclobutanecarbonyl, etc. hexanoyl isomers, cyclopentanecarbonyl isomers, etc.; C1-6 acyloxy such as formyloxy (e.g. -OC(O)H), acetyloxy, propionoyloxy butyryloxy, isobutyryloxy,
- cyclopropanecarbonyloxy pentanoyloxy isomers (such as pentanoyloxy, methylbutanoyloxy, pivaloyloxy, etc.), cyclobutanecarbonyloxy isomers (such as methylcyclopropanecarbony!oxy, cyclobutanecarbonyloxy, etc.), hexanoyloxy isomers, cyclopentanecarbonyloxy isomers, etc.; G2-6 alkyl carboxylate such as methyl carboxylate (e.g.
- R 2 may be H, or a moiety having from 0 to 20 carbon atoms, from 1 to 10 carbon atoms, or from 1 to 3 carbon atoms, and from 0 to 20 heteroatoms, 0 to 10 heteroatoms, 0 to 5 heteroatoms, or 0 to 3 heteroatoms selected from N, O, S, F, CI, I, Br, P, and combinations thereof, provided that at least 1 atom selected from C, N, 0, or S is present.
- R 2 is an alkyi amine, e.g. -R 3 -NR 4 R 5 , wherein R 3 is Ci-6 alkyi, and R 4 and R 5 are independently H or Ci-6 alkyi.
- Ph may be optionally substituted phenyl, including phenyl with 0, 1 , 2, 3, 4, or 5 substituents such as those substituents mentioned anywhere above with respect to a phenyl.
- R 2 is not an alkyi amine
- Ph has an alkyi amine substituent.
- Some useful prodrugs may include:
- the prodrug may further be combined with excipients to interfere with the reduction, or a saponification or other ester hydrolysis, or both.
- excipients for example, an buffer may be added to make hydrolysis of the ester more problematic.
- Some embodiments provide a method of inhibiting clandestine methamphetamine synthesis comprising treating a cold, allergy, congestion, hypotension, narcolepsy, urinary incontinence or bedwetting by administering a therapeutically effective amount of a prodrug of ephedrine or pseudoephedrine to a patient in need thereof.
- a prodrug of ephedrine is used to treat a cold, allergy, congestion, hypotension, narcolepsy, urinary incontinence or bedwetting. In some embodiments, a prodrug of ephedrine is used to treat a cold, allergy, congestion, urinary incontinence or bedwetting.
- treat includes the use of a compound, composition, therapeutically active agent, or drug in the diagnosis, cure, mitigation, treatment, or prevention of disease or other undesirable condition.
- prodrug is easily tested to optimize the difficulty in conversion of the prodrug to methamphetamine. This can be done by a variety of approaches.
- the prodrug could be tested by carrying out one of the many known clandestine methamphetamine preparation methods to determine the yield of methamphetamine, if any, made directly from the prodrug.
- the prodrug could be tested by carrying out one of many known hydrolysis procedures on the prodrug to determine the yield of methamphetamine recovered, and/or the product of the hydrolysis procedure could be subjected to the clandestine methamphetamine preparation method to determine the yield of methamphetamine for the combined process
- some embodiments provide a method of evaluating the difficulty of converting a prodrug of pseudoephedrine or ephedrine to methamphetamine comprising:
- This method may be practiced by determining the yield of the methamphetamine, pseudoephdrine or ephedrine without performing the reduction or recovery procedure.
- an individual who determines the yield of a reduction or a recovery procedure performed by another is practicing the method.
- a reduction procedure is any method known to be useful to convert pseudoephedrine or ephedrine to methamphetamine. Examples include various forms of the Vietnamese method or the P/l reduction method.
- a recovery procedure is any method known to be useful to convert a prodrug to a parent drug outside of the body. For example, acid or base catalyzed ester hydrolysis are recovery procedures.
- the product of the recovery procedure is the material that results from the recovery procedure which may or may not contain ephedrine or pseudoephedrine.
- Determining the yield of methamphetamine means to determine how much amphetamine resulted from a process as compared to how much of a precursor material was used or how much amphetamine was expected to result from a process.
- the reduction procedure is a dissolving metal reduction. In other embodiments, the reduction procedure involves phosphorous and iodine. In some embodiments, the recovery procedure is base-catalyzed hydrolysis of an ester. In other embodiments, the recovery procedure is acid-catalyzed hydrolysis of an ester.
- Example 1 A chemical manufacturer in Mexico prepares a prodrug of ephedrine for shipment to the United
- a large pharmaceutical manufacturer stores 100,000 kg of a prodrug of pseudoephedrine in a large warehouse for use in preparing dosage forms.
- criminals break in and steal 1 ,000 kg of the prodrug and sell it to a super-lab in Arizona.
- the super-lab is unable to produce any useful product.
- a pharmaceutical company introduces a commercial prodrug of pseudoephedrine to the market. Because the prodrug is now available, the Federal government bans all over-the-counter sales of pseudoephedrine, and severely restricts prescription sales of pseudoephedrine.
- the prodrug is used effectively by consumers to treat their cold symptoms.
- An operator of an STL purchases 100 g of the prodrug intending to make methamphetamine for personal use and small-scale sales. She runs a small batch using the Nazi method and tests part of on herself. After half an hour, she realizes that she is not experiencing any high and exclaims "this stuff is no good.” Frustrated, she tosses the product into the garbage and attempts to run a small batch using the P/l method. She again samples the product and experiences no high. Unable to obtain any decent methamphetamine, she checks herself into rehab and discontinues use of methamphetamine.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Emergency Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed herein are compounds and methods for using prodrugs of pseudoephedrine and ephedrine to inhibit illegal methamphetamine synthesis.
Description
METHODS, COMPOSITIONS, AND COMPOUNDS FOR THE REDUCTION OF ILLEGAL
METHAMPHETAMINE PRODUCTION
BACKGROUND
Methamphetamine abuse is a growing problem. A large part of this problem stems from the ease of synthesis of methamphetamine from the common legitimate medications ephedrine and pseudoephedrine. These compounds are converted to methamphetamine by a reduction reaction that is so simple to carry out that anyone can do it. It is estimated that 99% of clandestine drug laboratories in the US are involved in methamphetamine manufacture.
Ephedrine or pseudoephedrine is usually converted to methamphetamine by using either red phosphorous obtained from matches and iodine created in situ from HI (P/l method), or by the "Nazi method," which is a dissolving metal reduction that uses ammonia and lithium removed from batteries. The U.S. Drug Enforcement Agency (DEA) recognizes two classes of clandestine methamphetamine producers. The first class, called "super-labs," are those capable of making 10 pounds or more of methamphetamine in a 24-hour period. These labs are operated by criminal organizations. The second class, called small toxic labs (STL), are those that are operated independently. The STLs obtain their ephedrine or pseudoephedrine by purchasing an over the counter dosage form at a store or on the internet and extracting the drug. By contrast, the super-labs divert large amounts of the pseudoephedrine or ephedrine from legitimate uses. Although most labs are STLs, the super-labs actually produce a greater share of the methamphetamine being used in the US.
Clandestine methamphetamine production is more than just a drug problem, it is a safety and environmental problem. Methamphetamine labs often explode or catch fire. Furthermore, according to
the DEA, one pound of clandestine methamphetamine production yields 5-6 pounds of hazardous waste. In 2003, the cost to the DEA for cleanup of methamphetamine labs was $16 million.
Both technical and legal solutions to this problem have been proposed or implemented with varying degrees of success. In 2005, Murray and colleagues (US 6,852,891) proposed a "method of inhibiting or preventing the use of anhydrous ammonia as a solvent in a dissolving metal reduction process comprises adding to anhydrous ammonia a chemical reagent which is capable of scavenging solvated electrons generated when alkali or alkaline earth metal is dissolved in the anhydrous ammonia, the chemical reagent being added to the anhydrous ammonia such that when alkali metal is dissolved in the anhydrous ammonia containing the chemical reagent and thereafter ephedrine, pseudoephedrine or combination thereof is introduced to the anhydrous ammonia to produce a reaction product, the methamphetamine yield in the reaction product is below 50%, preferably below 10%, and more preferably below 1 %. Preferred chemical reagents include Fe(lll)citrate, ferrocene, 2- chloro-6-(trichloromethyl)pyridine and 1 ,1 ,1 ,2-tetrafluoroethane." However, this method is ineffective in reducing methamphetamine synthesis via the P/l method.
Booth and colleagues (US 6,495,529) claimed that (-)-pseudoephedrine, the enantiomer of the commercial (+)-pseudoephedrine was "useful for relieving nasal and bronchial congestion" and had "fewer side effects" than the commercial product. Reduction of this compound would yield the enantiomer of methamphetamine, which does not have the effects that users of methamphetamines seek. However, this use was conceived in 1998, and no product has resulted to date.
Congress enacted the Combat Methamphetamine Epidemic Act in 2005, which required sales of ephedrine and pseudoephedrine over-the-counter products be stored behind the counter, restricted daily and monthly sales quantities, and required that sales be recorded. Most states have also enacted legislation to control over-the-counter sales of ephedrine and pseudoephedrine products.
Other compounds, such as phenylephrine, have replaced pseudoephedrine in some products. But pseudoephedrine is still in demand because for many people, phenylephrine is significantly less effective in relieving congestion and other symptoms.
Despite these efforts, the methamphetamine problem persists. Thus, there continues to be a need for additional methods of controlling this problem.
DESCRIPTION
Clandestine methamphetamine synthesis could be substantially curtailed by replacing the pseudoephedrine and ephedrine that is manufactured, transported, sold, stored, or administered to a mammal, including a human being, with prodrugs of the pseudoephedrine and ephedrine. Thus,
pseudoephedrine or ephedrine would no longer be available for a criminal to steal or purchase for conversion to methamphetamine because it is replaced by the prodrug. The prodrug would be more difficult than pseudoephedrine and ephedrine to convert to methamphetamine, thus decreasing the availability of the drug and discouraging clandestine manufacture. Thus, it may have a substantial impact upon the STLs whose operators are unsophisticated in chemical methods, and reduce the hazard and environmental disaster associated with these labs. It may also provide a substantial barrier to the operators of super-labs. At the same time, because it is a prodrug instead of a different active altogether, it may still provide the relief characteristic of pseudoephedrine or ephedrine to mammals in need of that relief.
Manufacturing a prodrug of ephedrine or pseudoephedrine to replace ephedrine or
pseudoephedrine includes manufacturing the prodrug in any situation where pseudoephrine or ephedrine might be manufactured for a similar purpose. For example, in some embodiments, the prodrug would be manufactured for use in treating a mammal, including a human being, where pseudoephedrine or ephedrine might be used to treat that mammal.
Selling a prodrug of ephedrine or pseudoephedrine to replace ephedrine or pseudoephedrine includes selling the prodrug in any situation where pseudoephrine or ephedrine might also be sold for a similar purpose. For example, in some embodiments, the prodrug would be sold for use in treating a mammal, including a human being, where pseudoephedrine or ephedrine might be used to treat that mammal.
Transporting a prodrug of ephedrine or pseudoephedrine to replace ephedrine or
pseudoephedrine includes transporting the prodrug in any situation where pseudoephrine or ephedrine might also be transported for a similar purpose. For example, the prodrug would be transported to a location for use in treating a mammal, including a human being, where pseudoephedrine or ephedrine might be used to treat that mammal.
Storing a prodrug of ephedrine or pseudoephedrine to replace ephedrine or pseudoephedrine includes storing the prodrug in any situation where pseudoephrine or ephedrine might also be stored for a similar purpose. For example, the prodrug would be stored in a location for use in treating a mammal, including a human being, where pseudoephedrine or ephedrine might be used to treat that mammal.
Administering a prodrug of ephedrine or pseudoephedrine to replace ephedrine or
pseudoephedrine includes administering the prodrug in any situation where pseudoephrine or ephedrine might also be administered for a similar purpose. For example, the prodrug would be administered to a mammal, including a human being, where pseudoephedrine or ephedrine might be administered to treat that mammal.
The more ephedrine or pseudoephedrine that is replaced by a prodrug, the more clandestine methamphetamine synthesis may be prevented. The ephedrine or pseudoephedrine replaced may be in a single composition or several different compositions, such as in a powder form; or in one or more units of at least one dosage form. Thus, some embodiments include a composition or several different compositions, or multiple units of a dosage form, comprising a prodrug of ephedrine or
pseudoephedrine. The composition, compositions, or dosage forms comprising the prodrug may be manufactured, sold, transported, or stored to replace ephedrine or pseudoephedrine. In these embodiments, the amount of the prodrug may be at least about 1 g, about 100 g, about 1 kg, or about 10 kg, up to about 1 ,000 kg, about 10,000 kg, about 100,000 kg, or about 1 ,000,000 kg of a prodrug of ephedrine or pseudoephedrine
Dosage forms may be provided for administration of the prodrug to a mammal, including a human being, such as a human being to treat a condition normally treated by ephedrine or pseudoephedrine.
The dosage forms may comprise any therapeutically effective amount of the prodrug. In some embodiments the dosage form comprises at least about 0.00003 moles, about 0.00006 moles, about
0.00009 moles, about 0.0002 moles, about 0.0004 moles, about 0.0007 moles, up to about 0.002 moles or about 0.007 moles.
The term "prodrug" has the ordinary meaning known to one of ordinary skill in the art. In some embodiments, a prodrug includes a compound which is converted to a therapeutically active compound after administration to a mammal such as a human being. For example, conversion may occur by hydrolysis of an ester group or some other biologically labile group. Prodrug preparation is well known in the art. For example, "Prodrugs and Drug Delivery Systems," which is a chapter in Richard B.
Silverman, Organic Chemistry of Drug Design and Drug Action, 2d Ed., Elsevier Academic Press:
Amsterdam, 2004, pp. 496-557, provides further detail on the subject.
In some embodiments, the prodrug may comprise a derivative of the benzylic hydroxide of ephedrine or pseudoephedrine. In some embodiments, the prodrug may be an ester of the benzylic hydroxide of ephedrine or pseudoephedrine. In some embodiments, the prodrug may be a stable compound having one of the formulas:
wherein X is a single bond, CO, C02) CON, S, P03, S02NH, CH20, CH2OCO, or C2H4OCO2,
R is H, or a moiety having from 0 to 30 carbon atoms, from 4 to 30 carbon atoms, or from 10 to 30 carbon atoms, and from 0 to 30 heteroatoms, 0 to 20 heteroatoms, 0 to 10 heteroatoms, or 0 to 5 heteroatoms selected from N, O, S, F, CI, I, Br, P, and combinations thereof, provided that at least 1 atom selected from C, N, O, or S is present.
Unless otherwise indicated, when a chemical structural feature such as phenyl is referred to as being "optionally substituted," it is meant that the feature may have no substituents (i.e. be unsubstituted) or may have one or more substituents. A feature that is "substituted" has one or more substituents. The term "substituent" has the ordinary meaning known to one of ordinary skill in the art. In some embodiments, the substituent is an ordinary organic moiety known in the art, which may have a molecular weight (e.g. the sum of the atomic masses of the atoms of the substituent) of: at least about 14 g/mol, less than about 500 g/mol, about 300 g/mol, about 200 g/mol, about 100 g/mol, and/or about 50 g/mol. In some embodiments, the substituent comprises: about 0-30, about 0-20, about 0-10, or about 0-5 carbon atoms; and about 0-30, about 0-20, about 0-10, or about 0-5 heteroatoms independently selected from: N, O, S, P, Si, F, CI, Br, I, and combinations thereof; provided that the substituent comprises at least one atom selected from: C, N, O, S, P, Si, F, CI, Br, and I. Examples of substituents include, but are not limited to, alkyl, alkenyl, alkynyl, carbazolyl, aryl, diarylamino, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, protected hydroxy, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O- carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfenyl, suifinyl, sulfonyl, haloalkyl, haloalkoxyl, trihalomethanesulfonyl, trihalomethanesulfonamido, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof.
In some embodiments, a stable compound includes a compound which is sufficiently stable to store under a normal atmosphere for at least 24 hours at room temperature.
Unless otherwise indicated, reference to a compound should be construed broadly to include pharmaceutically acceptable salts, tautomers, alternate solid forms, non-covalent complexes, and combinations thereof, of a chemical entity of the depicted structure or chemical name.
A pharmaceutically acceptable salt includes any salt of the parent compound that is suitable for administration to an animal or human. A pharmaceutically acceptable salt also refers to any salt which may form in vivo as a result of administration of an acid, another salt, or a prodrug which is converted into an acid or salt. A salt comprises one or more ionic forms of the compound, such as a conjugate
acid or base, associated with one or more corresponding counter-ions. Salts can form from or incorporate one or more deprotonated acidic groups (e.g. carboxylic acids), one or more protonated basic groups (e.g. amines), or both (e.g. zwitterions).
Tautomers include isomers that are in rapid equilibrium with one another. For example, tautomers may be related by transfer of a proton, hydrogen atom, or hydride ion.
A structure is intended to include every possible stereoisomer, both pure or in any possible mixture.
Alternate solid forms include different solid forms than those that may result from practicing the procedures described herein. For example, alternate solid forms may be polymorphs, different kinds of amorphous solid forms, glasses, and the like.
Non-covalent complexes include complexes that may form between the compound and one or more additional chemical species that do not involve a covalent bonding interaction between the compound and the additional chemical species. They may or may not have a specific ratio between the compound and the additional chemical species. Examples might include solvates, hydrates, charge transfer complexes, and the like.
Generally these, compounds may be prepared by combining the corresponding acyl chloride or carboxylic acid anhydride with ephedrine or pseudoephedrine, possibly in the presence of a base. They also may be prepared from an ester such as the methyl or ethyl ester by transesterification. These kinds of reactions are well known in the art. For example, see Smith and March, March's Organic Chemistry: Reactions, Mechanisms, and Structure, 5th Ed., New York: John Wiley & Sons, Inc., pp. 482-492, and 523-524.
A prodrug leaving group is the compound that would result if only the bond between pseudoephedrine and the remaining part of the molecule were hydrolyzed. Thus, in the structure above, the prodrug leaving group is RCO2H.
In some embodiments, R is hydrocarbyl having from 1 to 24 carbo i atoms.
Hydrocarbyl includes compounds having only carbon and hydrogen.
In some embodiments, R is alkyl having from 1 to 12 carbon atoms, such as methyl (CH3); ethyl (C2H5); propyl isomers (C3H7) such as propyl, isopropyl, etc.; cyclopropyl, (C3H6); butyl isomers (C4H9); cyclobutyl isomers (C4H8) such as cyclobutyl, methylcyclopropyl, etc.; pentyl isomers (C5H11); cyclopentyl isomers (C5H10); hexyl isomers (C6H13); cyclohexyl isomers (C6H12); heptyl isomers (C7H13); cycloheptyl isomers (C7H14); octyl isomers (C8H17); cyclooctyl isomers (CeHi6); nonyl isomers (C9H17); cyclononyl isomers (CgHis); decyl isomers (C10H21); cyclodecyl isomer (C10H20); undecyl isomers (C11H23); cycloundecyl isomers (C11H22); dodecyl isomers (C12H25); cyclododecyl isomers (C12H24); etc.
11
20
With respect to any relevant structural feature depicted or otherwise identified herein, Ra may be H; C1-12 alkyl such as methyl (CH3); ethyl (C2H5); propyl isomers (C3H7) such as propyl, isopropyl, etc.; cyclopropyl, (C3H6); butyl isomers (C4H9); cyclobutyl isomers (C4H8) such as cyclobutyl, methylcyclopropyl, etc.; pentyl isomers (C5H11); cyclopentyl isomers (C5H10); hexyl isomers (G6H13); cyclohexyl isomers (C6H12); heptyl isomers (C7H13); cycloheptyl isomers (C7H14); octyl isomers (CsHi7); cyclooctyl isomers (CeHie); nonyl isomers (C9H17); cyclononyl isomers (CgHia); decyl isomers (C10H21); cyclodecyl isomer (dohko); undecyl isomers (C11H23); cycloundecyl isomers (C11H22); dodecyl isomers (C12H25); cyclododecyl isomers (C12H24); or optionally substituted phenyl, such as unsubstituted phenyl, or phenyl substituted with 1, 2, or 3 substituents selected from: C1-3 alkyl (such as methyl, ethyl, propyl, isopropyl, cyclopropyl, etc.), OH, OCH3, OC2H5, OC3H7, NH2, NHCH3l N(CH3)2, OCOCH3, C02H, CO2CH3, CO2C2H5, etc. In some embodiments, Ra may be H, CH3, CH2CH3, C(CH3)2l C4H9, or unsubstituted phenyl.
With respect to any relevant structural feature depicted or otherwise identified herein, Rb may be H; C1-12 alkyl such as methyl (CH3); ethyl (C2H5); propyl isomers (C3H7) such as propyl, isopropyl, etc.; cyclopropyl, (C3H6); butyl isomers (C4H9); cyclobutyl isomers (C4H8) such as cyclobutyl, methylcyclopropyl, etc.; pentyl isomers (C5H11); cyclopentyl isomers (C5H10); hexyl isomers (C6H13); cyclohexyl isomers (C6H12); heptyl isomers (C7H13); cycloheptyl isomers (C7H14); octyl isomers (C8H17); cyclooctyl isomers (C8Hi6); nonyl isomers (C9H17); cyclononyl isomers (C9H18); decyl isomers (C10H21); cyclodecyl isomer (C10H20); undecyl isomers (C11H23); cycloundecyl isomers (C11H22); dodecyl isomers (C12H25); cyclododecyl isomers (C12H24); or optionally substituted phenyl, such as unsubstituted phenyl, or phenyl substituted with 1 , 2, or 3 substituents selected from: C1-3 alkyl (such as methyl, ethyl, propyl, isopropyl, cyclopropyl, etc.), OH, OCH3, OC2H5, OC3H7, NH2, NHCH3, N(CH3)2, OCOCH3, C02H, CO2CH3, CO2C2H5, etc. In some embodiments, Rb may be H, CH3, CH2CH3, C(CH3)2, C4H9, or unsubstituted phenyl.
With respect to any relevant structural feature depicted or otherwise identified herein, Rc may be H; C1-12 alkyl such as methyl (CH3); ethyl (C2H5); propyl isomers (C3H7) such as propyl, isopropyl, etc.; cyclopropyl, (C3H6); butyl isomers (C4Hg); cyclobutyl isomers (C4H8) such as cyclobutyl, methylcyclopropyl, etc.; pentyl isomers (C5H11); cyclopentyl isomers (C5H10); hexyl isomers (C6H13); cyclohexyl isomers (C6H12); heptyl isomers (C7H13); cycloheptyl isomers (C7H14); octyl isomers (C8Hi7); cyclooctyl isomers (C8Hi6); nonyl isomers (C9H17); cyclononyl isomers (CgHis); decyl isomers (C10H21); cyclodecyl isomer (CioH2o); undecyl isomers (C11H23); cycloundecyl isomers (C11H22); dodecyl isomers (C12H25); cyclododecyl isomers (C12H24); or optionally substituted phenyl, such as unsubstituted phenyl, or phenyl substituted with 1 , 2, or 3 substituents selected from: C1-3 alkyl (such as methyl, ethyl, propyl, isopropyl, cyclopropyl, etc.), OH, OCH3, OC2H5, OC3H7, NH2, NHCH3, N(CH3)2, OCOCHs, CO2H, CO2CH3, CO2C2H5, etc. In some embodiments, Rc may be H, CH3, CH2CH3, C(CH3)2, C4H9, or unsubstituted phenyl.
With respect to any relevant structural feature depicted or otherwise identified herein, Rd may be H; C1-12 alkyl such as methyl (CH3); ethyl (C2H5); propyl isomers (C3H7) such as propyl, isopropyl, etc.; cyclopropyl, (C3H6); butyl isomers (C4Hg); cyclobutyl isomers (C4H8) such as cyclobutyl, methylcyclopropyl, etc.; pentyl isomers (C5H11); cyclopentyl isomers (C5H10); hexyl isomers (C6H13); cyclohexyl isomers (C6H12); heptyl isomers (C7H13); cycloheptyl isomers (C7H14); octyl isomers (C8Hi7); cyclooctyl isomers (C8Hi6); nonyl isomers (C9H17); cyclononyl isomers (CgHie); decyl isomers (C10H21); cyclodecyl isomer (Ci0H2o); undecyl isomers (C11H23); cycloundecyl isomers (C11H22); dodecyl isomers (C12H25); cyclododecyl isomers (C12H24); or optionally substituted phenyl, such as unsubstituted phenyl, or phenyl substituted with 1 , 2, or 3 substituents selected from: C1-3 alkyl (such as methyl, ethyl, propyl, isopropyl, cyclopropyl, etc.), OH, OCH3, OC2H5, OC3H7l NH2, NHCH3, N(CH3)2, OCOCH3, C02H, COH, CO2CH3, CO2C2H5, NO2, etc. In some embodiments, Rd may be H, CH3, CH2CH3, C(CH3)2, C4H9, or unsubstituted phenyl.
With respect to any relevant structural feature depicted or otherwise identified herein, a may be 0, 1 , 3, 4, 5, or 6.
With respect to any relevant structural feature depicted or otherwise identified herein, A1 may be a bond, CO, or C02.
With respect to any relevant structural feature depicted or otherwise identified herein, A2 may be O, S, or Ra
With respect to any relevant structural feature depicted or otherwise identified herein, A3 may be a bond, CO, or C02.
With respect to any relevant structural feature depicted or otherwise identmea nerein, may be a bond, CO, or C02.
In some embodiments, the prodrug leaving group, or RCO2H is a fatty acid. Fatty acids include linear carboxylic acids which have an even number of carbon atoms. Examples include, but are not limited to:
Saturated fatty acids, which have no C=C moieties and include, but are not limited to, myristic acid, palmitic acid, stearic acid, arachidic acid, and behenic acid.
• unsaturated fatty acids, including, but are not limited to, the following:
• monounsaturated fatty acids, which have one C=C group such as palmitoleic acid and oleic acid;
• diunsaturated fatty acids, which have two C=C groups, such as linoleic acid;
• triiunsaturated fatty acids, which have three C=C groups, such as a-linolenic acid and γ- linolenic acid;
• tetraunsaturated fatty acids, which have four C=C groups/such as arachidonic acid; and
• pentaunsaturated fatty acids, which have five C=C groups, such as eicosapentaenoic acid.
• Some fatty acids have 14 carbon atoms such as myristic acid.
• Some fatty acids have 16 carbon atoms such as palmitic and palmitoleic acid.
• Some fatty acids have 18 carbon atoms such as stearic acid, oleic acid, linoleic acid, a- linolenic a, and γ-linolenic acid.
• Some fatty acids have 20 carbon atoms such as eicosapentaenoic acid.
It is believed that these compounds may not readily be converted to methamphetamine by either the P/HI method or by the "Nazi method." It is also believed that an attempt at saponification of these compounds followed by an attempt at reducing the resulting hydroxyl method will provide very low yields of methamphetamine with a large quantity of impurities, making isolation of a drug which provides a satisfactory result to the end user difficult.
In some embodiments, RCO2H is an amino acid, such as glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, asparagine, glutamine, tyrosine, cysteine, lysine, arginine, histidine, aspartic acid, glutamic acid, or a salt, ester, amide, carbonate or carbamate of an amino acid.
To further complicate the reaction by the P/l method, a moiety which further interferes with the reaction may be added. One such moiety is a ketone. Since iodine is formed in situ in the presence of acid in this method of amphetamine synthesis, the a-carbon of a ketone may react to form an a- iodoketone. Thus, this side reaction may further interfere with preparation of methamphetamine.
Another moiety which may interfere with both the P/l method and the Nazi method is hydroxyl (-OH). In particular benzylic hydroxyl may be especially problematic because of its similarity to the hydroxyl of ephedrine or pseudoephedrine to be reduced. Polyol moieties, such as those from sugars or other carbohydrates may also interfere with the reduction.
Another moiety which may interfere with the Nazi method is phenyl or aryl. Phenyl or aryi with an electronic withdrawing substituent may be particularly problematic for a clandestine manufacturer.
In some embodiments, R is has from 1 to 24 carbon atoms and from 1 to 24 oxygen atoms. In some embodiments, each oxygen atom is part of a hydroxyl, keto (C=0), acetal, hemiacetal, ketal, hemiketal, or an ester moiety.
where R1 and R2 are independently hydrocarbyl.
A hemiacetal moiety includes:
wherein R1 is hydrocarbyl.
where R1 and R2 are independently hydrocarbyl.
wherein R1 is hydrocarbyl.
An ester moiety is -CO2-, where both the carbon and the saturated oxygen atom are directly attached to carbon atoms.
Useful examples of R include:
[a] hydroxymethyl substituted phenyl, such as hydroxymethylphenyl,
di(hydroxymethyl)phenyl, tri(hydroxymethyl)phenyl, tetra(hydroxymethyl)phenyl, and penta(hydroxymethyl)phenyl;
[b] other benzylic alcohols such as 1-hydroxyethylphenyl, 1-hydroxypropylphenyl, and the like, and di-, tri-, tetra-, and penta-subsituted benzylic alcohols;
[c] phenyl with one or more keto and/or aldehyde moieties in the benzylic position;
[d] phenyl with a combination of different benzylic alcohol, keto, and/or aldehyde moieties;
[e] -(CHOH)nCH2OH, wherein n is from 0 to 23;
[f] -(CHOH)n(C=0)H, wherein n is from 0 to 23;
[g] -(CHOH)n(C=0)(CHOH)mCH2OH, wherein n + m is from 0 to 22;
[h] phenyl, including:
[i] phenyl with one or more electron withdrawing substituents such as nitro, CN, halo, acyl, acyloxy, CF3, CO2H, and the like;
[ii] phenyl with other substituents including:
• alkyl, such as methyl, ethyl, propyl isomers, butyl isomers, and the like;
alkoxy, such as methoxy, ethoxy, etc.;
hydroxyl;
amino, such as NH2, NH-alkyl, N(alkyl)2, etc.;
and the like.
In one embodiment the prodrug leaving group is a keto-acid or a polyketo-acid. In other words the prodrug leaving group is a carboxylic acid that has one or more ketone functional groups.
The prodrug may be modified to further interfere with methamphetamine synthesis by adding a moiety which is difficult to separate from ephedrine or pseudoephedrine during work-up of a saponification. Part of the work up procedure of methamphetamine synthesis relies on protonating the amine to make the compound water soluble, washing out impurities, and then recovering the methamphetamine by deprotonating the amine. Thus addition of an amine moiety could further complicate the separation process. In particular, the combination of an amine with one or more hydroxyl moieties could provide an impurity upon saponification that is difficult to separate and interferes with the reduction. For example, a prodrug which saponifies to form glucosamine would be useful.
Many prodrugs may be prepared by reacting an acid chloride (Cl-X-R) with pseudoephedrine or ephedrine, as shown in Scheme A. A base may be used for some reactions to help remove HCI
generated during the reaction. In some embodiments, the hydrochloride salt of tne amine group may be reacted with the acid chloride.
Scheme A
Dicarboxylic acid ester prodrugs may be prepared by reacting a dicarboxylic acid anhydride with pseudoephedrine or ephedrine. Scheme B illustrates an example that may be generalized to many other dicarboxylic acids.
Scheme B
Some dicarboxylic acid diester prodrugs may be prepared by reaction with an acyl chloride ester. The acyl chloride ester may be prepared by reacting a dicarboxylic acid anhydride with an alcohol, followed by reaction with thionyl chloride or oxallyl chloride. Scheme C illustrates an example
or oxallyl chloride
Scheme C
Some carbamate protected amino acid based ester prodrugs may be prepared by reacting the amino acid with excess phosgene, possibly in the presence of a base, followed by an alcohol such as RaOH. Reaction with water under mild conditions may free the carboxylic acids by hydrolysis, which
may be converted to the acyl chloride using oxallyl chloride or another similar reagent. I his protected amino acid chloride may then be reacted with ephedrine or pseudoephedrine. Scheme D shoes an example that may be generalized to many compounds.
Scheme D
Some amide protected amino acid based ester prodrugs may be prepared in a manner similar to the carbamates. Excess acyl chloride is reacted with the amino acids and the acid anhydrides are hydrolyzed. The resulting protected amino acids may be converted to the amino acid acyl chloride using oxallyl chloride or another similar reagent. This protected amino acid chloride may then be reacted with ephedrine or pseudoephedrine. Scheme E shoes an example that may be generalized to many compounds.
Scheme E In any of schemes A-E, the amine of pseudoephedrine or ephedrine may be protected. For example, the compound below may be used in place of pseudoephedrine or ephedrine to obtain an N- protected prodrug.
One useful prodrug is depicted below. There are several ways it may be prepared. One method would to convert acetylsalicylic acid, i.e. aspirin, to the corresponding acyl chloride, and reacting with ephedrine or pseudoephedrine by methods known in the art, as shown in Scheme 1 below.
Scheme 1
Another useful prodrug is an ester of an aldonic acid, such as the compound depicted below.
Examples include, but are not limited to: glyceronic acid, erythronic acid, threonic acid, ribonic acid, arabinonic acid, xylonic acid, lyxonic acid, allonic acid, altronic acid, gluconic acid, mannonic acid, gulonic acid, idonic acid, galactonic acid, talonic acid, and the like.
These compounds may be prepared by a number of methods. For example, the hydroxyl groups of a sugar with a terminal aldehyde could be protected, the aldehyde could then be oxidized to a carboxylic acid, the acid converted to an anhydride or a acyl chloride, and the protecting groups removed, as shown in Scheme 2 below.
PG: protecting group
Scheme 2
The same basic idea could be extended to a number of different sugar related acids such as those derived from disaccharides and polysaccharides having a terminal aldehyde, or an acetal or hemiacetal moiety that may be converted to a carboxylic acid. Other sugar related acids that might be used include uronic acids, such as glucuronic acid, glacturonic acid, mannuronic acid; ascorbic acid; ribose, deoxyribose, fucose, and the like.
Sugar derivatives having other functionalities, such as amino sugars, might also be used in mine, is typical.
There are a number of ways these compounds could be prepared. Scheme 3 illustrates one method that might be used. The protected glucosamine is prepared as described in WO 03/022860. This compound is reacted with succinic anhydride to form the succinic acid ester shown. This is then converted to the acyl chloride and reacted with ephedrine or pseudoephedrine to give the protected product. The protected product is deprotected with ethylene diamine, followed by TFA or tosic acid as described in WO 03/022860.
Scheme 3
These sugar-derived prodrugs may be further modified by addition of a phenyl moiety. For example, benzoic acid could be added to one of the hydroxyl groups to form esters such as those shown below. The phenyl group may further interfere with methamphetamine synthesis, particularly by olving metal conditions.
In some embodiments, the prodrug leaving group comprises a phenyl ring comprising one or more substituents having a benzylic hydroxyl moiety and an amine moiety. The benzylic hydroxyl and the amine may be on the same substituent, or they may be on different substituents. In some embodiments, the benzylic hydroxyl moiety may be in the form of an ester which is formed by a linker, such as a dicarboxylic acid ester linker, which connects to the benzylic oxygen of pseudoephedrine or
ephedrine. For example, some prodrugs may be compounds represented by one ot the fallowing formulas:
With respect to any relevant structural feature depicted or otherwise identified herein, R1 may be hydrocarbyl, such as C1-12 hydrocarbyl, including -CH2-, -CH2CH2-, -CH=CH-, -C≡C-, -CH2CH2CH2- , -CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2CH2-, etc.; or optionally substituted aryl, such as substituted or unsubstituted phenyl. In some embodiments, the aryl or phenyl may have 0, 1 , 2, 3, or 4 substituents independently selected from: Ci-s alkyl, such as methyl, ethyl, propyl isomers, cyclopropyl, butyl isomers, cyclobutyl isomers (such as cyclobutyl, methylcyclopropyl, etc.), pentyl isomers, cyclopentyl isomers, hexyl isomers, cyclohexyl isomers, etc.; Ci-6 alkoxy, such as methoxy, ethoxy, propoxy isomers (e.g. isopropoxy, n-propoxyl, etc.), cyclopropoxy, butoxy isomers, cyclobutoxy isomers (such as cyclobutoxy, methylcyclobutoxy, etc.), pentoxy isomers, cyclopentoxy isomers, hexoxy isomers, cyclohexoxy isomers, etc.; Ci-s acyl such as formyl, acetyl, propionoyl butyryl, isobutyryl, cyclopropanecarbonyl, pentanoyl isomers (such as pentanoyl, methylbutanoyl, pivaloyl, etc.), cyclobutanecarbonyl isomers (such as methylcyclopropane carbonyl,
cyclobutanecarbonyl, etc.), hexanoyl isomers, cyclopentanecarbonyl isomers, etc.; C1-6 acyloxy such as formyloxy (e.g. -OC(O)H), acetyloxy, propionoyloxy butyryloxy, isobutyryloxy,
cyclopropanecarbonyloxy, pentanoyloxy isomers (such as pentanoyloxy, methylbutanoyloxy, pivaloyloxy, etc.), cyclobutanecarbonyloxy isomers (such as methylcyclopropanecarbony!oxy, cyclobutanecarbonyloxy, etc.), hexanoyloxy isomers, cyclopentanecarbonyloxy isomers, etc.; G2-6 alkyl carboxylate such as methyl carboxylate (e.g. CO2CH3), ethyl carboxylate, propyl carboxylate, isopropyl carboxylate, cyclopropyl carboxylate, butyl carboxylate isomers (such as butyl carboxylate, isobutyl carboxylate, etc.), cyclobutyl carboxylate isomers (such as cyclobutyl carboxylate, methylcyclopropyl carboxylate, etc.), pentyl carboxylate isomers, cyclopentyl carboxylate isomers, etc.; C1-6 -N-amides
such as -NH-formyl, -NH-acetyl, -NH-propionoyl -NH-butyryl, -NH-isobutyryl, -NH- cyclopropanecarbonyl, -NH-pentanoyl isomers (such as -NH-pentanoyl, -NH-methylbutanoyl, -NH- pivaloyl, etc.), -NH-cyclobutanecarbonyl isomers (such as -NH-methylcyclopropane carbonyl, -NH- cyclobutanecarbonyl, etc.), -NH-hexanoyl isomers, -NH-cyclopentanecarbonyl isomers, -N(CH3)- formyl, -N(CH3)-acetyl, -N(CH3)-propionoyl, -N(CH3)-butyryl, -N(CH3)-isobutyryl, -N(CH3)- cyclopropanecarbonyl, _-N(CH3)-pentanoyl isomers (such as -N(CH3)-pentanoyl, -N(CH3)- methylbutanoyl, -N(CH3)-pivaloyl, etc.), -N(CH3)-cyclobutanecarbonyl isomers (such as -N(CH3)- methylcyclopropane carbonyl, -N(CH3)-cyclobutanecarbonyl, etc.), -N(CH2CH3)-formyl, -N(CH2CH3)- acetyl, -N(CH2CH3)-propionoyl, -N(CH2CH3)-butyryl, -N(CH2CH3)-isobutyryl, -N(CH2CH3)- cyclopropanecarbonyl, etc.; F; CI; Br; I; nitro; CN, and the like.
With respect to any relevant structural feature depicted or otherwise identified herein, R2 may be H, or a moiety having from 0 to 20 carbon atoms, from 1 to 10 carbon atoms, or from 1 to 3 carbon atoms, and from 0 to 20 heteroatoms, 0 to 10 heteroatoms, 0 to 5 heteroatoms, or 0 to 3 heteroatoms selected from N, O, S, F, CI, I, Br, P, and combinations thereof, provided that at least 1 atom selected from C, N, 0, or S is present. In some embodiments, R2 is an alkyi amine, e.g. -R3-NR4R5, wherein R3 is Ci-6 alkyi, and R4 and R5 are independently H or Ci-6 alkyi.
With respect to any relevant structural feature depicted or otherwise identified herein, Ph may be optionally substituted phenyl, including phenyl with 0, 1 , 2, 3, 4, or 5 substituents such as those substituents mentioned anywhere above with respect to a phenyl. In some embodiments, if R2 is not an alkyi amine, then Ph has an alkyi amine substituent. These may be prepared by adapting methods described above or other methods well known in the art.
Some useful prodrugs may include:
The compounds depicted below are specifically contemplated for use herein. They may be prepared by methods known in the art, for example the following documents describe procedures which may be used to prepare one or more of these compounds: EP0313885; Auvinen, Acta
Pharmaceutica Fennica 87, 37-42 (1978); Marvola, Acta Pharmacol, et. toxicol. 1976, 38, 474-489; Marvola, Acta Pharmacol, et. toxicol. 1977, 40, 22-32; Trepanier, J. Med. Chem. 1973, 16, 342; Welsh, J. Am. Chem. Soc. 69, 128; Pfanz, Arch Pharm 1955, 288:65-72; Welsh, J. Org. Chem. 32, 119; and Fodor, J. Org. Chem. 14, 337.
42
43
In some embodiments, the prodrug may further be combined with excipients to interfere with the reduction, or a saponification or other ester hydrolysis, or both. For example, an buffer may be added to make hydrolysis of the ester more problematic.
Some embodiments provide a method of inhibiting clandestine methamphetamine synthesis comprising treating a cold, allergy, congestion, hypotension, narcolepsy, urinary incontinence or
bedwetting by administering a therapeutically effective amount of a prodrug of ephedrine or pseudoephedrine to a patient in need thereof.
In some embodiments, a prodrug of ephedrine is used to treat a cold, allergy, congestion, hypotension, narcolepsy, urinary incontinence or bedwetting. In some embodiments, a prodrug of ephedrine is used to treat a cold, allergy, congestion, urinary incontinence or bedwetting.
For the purposes of this disclosure, "treat," "treating," or "treatment" includes the use of a compound, composition, therapeutically active agent, or drug in the diagnosis, cure, mitigation, treatment, or prevention of disease or other undesirable condition.
Although any prodrug is believed to be useful in the disclosed methods, compositions, and dosage forms disclosed herein, a prodrug is easily tested to optimize the difficulty in conversion of the prodrug to methamphetamine. This can be done by a variety of approaches. First, the prodrug could be tested by carrying out one of the many known clandestine methamphetamine preparation methods to determine the yield of methamphetamine, if any, made directly from the prodrug. Second, the prodrug could be tested by carrying out one of many known hydrolysis procedures on the prodrug to determine the yield of methamphetamine recovered, and/or the product of the hydrolysis procedure could be subjected to the clandestine methamphetamine preparation method to determine the yield of methamphetamine for the combined process
Thus, some embodiments provide a method of evaluating the difficulty of converting a prodrug of pseudoephedrine or ephedrine to methamphetamine comprising:
a. determining the yield of methamphetamine obtained by performing a reduction
procedure on the prodrug,
b. determining the yield of pseudoephedrine or ephedrine obtained by performing a recovery procedure on the prodrug, or
c. determining the yield of methamphetamine obtained by performing a recovery
procedure on the prodrug and a reduction procedure on the product of the recovery procedure.
This method may be practiced by determining the yield of the methamphetamine, pseudoephdrine or ephedrine without performing the reduction or recovery procedure. Thus, for example an individual who determines the yield of a reduction or a recovery procedure performed by another is practicing the method.
A reduction procedure is any method known to be useful to convert pseudoephedrine or ephedrine to methamphetamine. Examples include various forms of the Nazi method or the P/l reduction method.
A recovery procedure is any method known to be useful to convert a prodrug to a parent drug outside of the body. For example, acid or base catalyzed ester hydrolysis are recovery procedures.
The product of the recovery procedure is the material that results from the recovery procedure which may or may not contain ephedrine or pseudoephedrine.
Determining the yield of methamphetamine means to determine how much amphetamine resulted from a process as compared to how much of a precursor material was used or how much amphetamine was expected to result from a process.
In some embodiments, the reduction procedure is a dissolving metal reduction. In other embodiments, the reduction procedure involves phosphorous and iodine. In some embodiments, the recovery procedure is base-catalyzed hydrolysis of an ester. In other embodiments, the recovery procedure is acid-catalyzed hydrolysis of an ester.
Example 1 A chemical manufacturer in Mexico prepares a prodrug of ephedrine for shipment to the United
States for medicinal use. While a 10,000 kg shipment is being made, criminals hijack the truck and smuggle it into the United States. A super-lab purchases the prodrug from the criminals, and attempts to convert the prodrug to methamphetamine. The resulting product produces no high, and the operators of the super-lab are unable to sell the product.
Example 2
A large pharmaceutical manufacturer stores 100,000 kg of a prodrug of pseudoephedrine in a large warehouse for use in preparing dosage forms. Criminals break in and steal 1 ,000 kg of the prodrug and sell it to a super-lab in Arizona. The super-lab is unable to produce any useful product.
Example 3
A pharmaceutical company introduces a commercial prodrug of pseudoephedrine to the market. Because the prodrug is now available, the Federal government bans all over-the-counter sales of pseudoephedrine, and severely restricts prescription sales of pseudoephedrine. The prodrug is used effectively by consumers to treat their cold symptoms. An operator of an STL purchases 100 g of the prodrug intending to make methamphetamine for personal use and small-scale sales. She runs a small batch using the Nazi method and tests part of on herself. After half an hour, she realizes that
she is not experiencing any high and exclaims "this stuff is no good." Frustrated, she tosses the product into the garbage and attempts to run a small batch using the P/l method. She again samples the product and experiences no high. Unable to obtain any decent methamphetamine, she checks herself into rehab and discontinues use of methamphetamine.
Claims
1. A commercial dosage form comprising a therapeutically effective amount of a prodrug of ephedrine or pseudoephedrine.
2. The dosage form of claim 1 which comprises a prodrug of pseudoephedrine.
3. The dosage form of claim 1 which comprises a prodrug of ephedrine.
4. The dosage form of claim 1 which comprises from about 0.00003 moles to about 0.02 moles of said prodrug.
5. The dosage form of claim 1 which comprises from about 0.00009 moles to about 0.002 moles of said prodrug.
6. A method of inhibiting methamphetamine synthesis comprising manufacturing, selling, transporting, or storing a prodrug of ephedrine or pseudoephedrine to replace ephedrine or pseudoephedrine.
7. The method of claim 6, wherein the quantity of ephedrine or pseudoephedrine replaced is greater than about 1 g.
8. The method of claim 7, wherein the quantity of ephedrine or pseudoephedrine replaced is from about 1 g to about 100,000,000 kg.
9. The method of claim 8 wherein the quantity of ephedrine or pseudoephedrine replaced is from about 10 g to about 100,000 kg.
10. A composition comprising a prodrug of ephedrine or pseudoephedrine in a quantity of from about 1 g to about 10,000 kg.
11. The composition of claim 10 wherein the prodrug is a stable compound having the formula
wherein R is H, or a moiety consisting of:
a. from 0 to 30 carbon atoms,
b. from 0 to 91 hydrogen atoms, and c. from 0 to 30 atoms selected from: N, 0, S, F, CI, I, Br, P, and combinations thereof.
12. A method of inhibiting methamphetamine synthesis comprising treating a cold, allergy, congestion, hypotension, narcolepsy, urinary incontinence or bedwetting by administering a therapeutically effective amount of a prodrug of ephedrine or pseudoephednne to a patient in need thereof.
13. A method of inhibiting methamphetamine synthesis comprising manufacturing, selling, transporting, or storing a prodrug of ephedrine or pseudoephednne at a quantity of from about 1 g to about 100,000,000 kg.
14. The method of claim 12, comprising manufacturing/ selling, transporting, or storing a prodrug of ephedrine or pseudoephednne at a quantity of from about 10 g to about 100,000,000 kg.
15. A plurality of units of at least one dosage form comprising a quantity of from about 1 g to about 10,000 kg of a prodrug of ephedrine or pseudoephednne.
16. A method of evaluating the difficulty of converting a prodrug of pseudoephednne or ephedrine to methamphetamine comprising:
a. determining the yield of methamphetamine obtained by performing a reduction
procedure on the prodrug,
b. determining the yield of pseudoephednne or ephedrine obtained by performing a
recovery procedure on the prodrug, or
c. determining the yield of methamphetamine obtained by performing a recovery procedure on the prodrug and a reduction procedure on the product of the recovery procedure.
17. The method of claim 16 wherein the reduction procedure is a dissolving metal reduction.
18. The method of claim 16 wherein the reduction procedure involves phosphorous and iodine.
19. The method of claim 16 wherein the recovery procedure is base-catalyzed hydrolysis of an ester.
20. The method of claim 16 wherein the recovery procedure is acid-catalyzed hydrolysis of an ester.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161531900P | 2011-09-07 | 2011-09-07 | |
US61/531,900 | 2011-09-07 | ||
US201261612304P | 2012-03-17 | 2012-03-17 | |
US61/612,304 | 2012-03-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013036567A2 true WO2013036567A2 (en) | 2013-03-14 |
WO2013036567A3 WO2013036567A3 (en) | 2013-04-18 |
Family
ID=47832760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/053850 WO2013036567A2 (en) | 2011-09-07 | 2012-09-06 | Methods, compositions, and compounds for the reduction of illegal methamphetamine production |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013036567A2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000015261A1 (en) * | 1998-09-10 | 2000-03-23 | Warner-Lambert Company | Compositions comprising sympathomimetic amine salts unsuitable for illegal use |
WO2009012590A1 (en) * | 2007-07-23 | 2009-01-29 | Kingsway Pharmaceuticals Inc. | Therapeutic formulations for the treatment of cold and flu-like symptoms |
-
2012
- 2012-09-06 WO PCT/US2012/053850 patent/WO2013036567A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000015261A1 (en) * | 1998-09-10 | 2000-03-23 | Warner-Lambert Company | Compositions comprising sympathomimetic amine salts unsuitable for illegal use |
WO2009012590A1 (en) * | 2007-07-23 | 2009-01-29 | Kingsway Pharmaceuticals Inc. | Therapeutic formulations for the treatment of cold and flu-like symptoms |
Non-Patent Citations (1)
Title |
---|
MU L. ET AL.: 'Synthesis of oxazolidines from ephedrines as potential prodrugs' YAO XUE XUE BAO vol. 27, no. 5, 1992, pages 336 - 44 & DATABASE PUBMED Database accession no. 1442053 * |
Also Published As
Publication number | Publication date |
---|---|
WO2013036567A3 (en) | 2013-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240182473A1 (en) | Compounds useful in hiv therapy | |
JP5167446B2 (en) | Buprenorphine derivatives and uses thereof | |
JPH0354952B2 (en) | ||
EP2102225A1 (en) | Alpha-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient | |
ME01295B (en) | Nalmefene di-ester prodrugs | |
AU2021273632A1 (en) | N-acylethanolamide derivatives and uses thereof | |
DeWit et al. | Design, synthesis, and cyclization of 4-aminobutyric acid derivatives: potential candidates as self-immolative spacers | |
JPH07149786A (en) | Glyceroglycolipid and carcinogenic promoter inhibitor | |
ES2201482T3 (en) | DERIVATIVES OF MORPHINE. | |
WO2013036567A2 (en) | Methods, compositions, and compounds for the reduction of illegal methamphetamine production | |
JP3538606B2 (en) | Water-soluble prodrug compound containing the residue of paclitaxel or a derivative thereof, method for producing the same, and pharmaceutical composition containing the same | |
JP4233262B2 (en) | Carbasugar amine derivatives and glycosidase inhibitors using the same | |
WO2021257851A1 (en) | Thyromimetics | |
WO2013014604A1 (en) | Multicomponent crystalline system of ezetimibe and proline | |
CN110128315B (en) | Compound, preparation method and application thereof, glycosidase inhibitor | |
WO2014154122A1 (en) | Bicyclol amino-acid ester, preparation method for same, and application thereof | |
JP2004512303A (en) | 6-methoxy-2-naphthylacetic acid prodrug | |
EP1038534A2 (en) | Process for the preparation of a conjugate of pharmacologically active substances | |
Greenwald et al. | Selective phenolic acylation of 10-hydroxycamptothecin using poly (ethylene glycol) carboxylic acid | |
US20220110962A1 (en) | Analogues of oleuropein and oleacein and uses thereof | |
Chatterjee et al. | Synthesis, pharmacological activity and hydrolytic behavior of ethylenediamine and benzathine conjugates of ibuprofen | |
CN104860932B (en) | A kind of pyrazoline ketone compounds and its application | |
AU2014201874B2 (en) | Stilbenoid compounds as inhibitors for squamous carcinoma and hepatoma and uses thereof | |
US6730701B2 (en) | 6-methoxy-2-naphthylacetic acid prodrugs | |
CZ20021435A3 (en) | Prodrugs of 6-methoxy-2-naphthylacetic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 27-06-2014) |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12829890 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12829890 Country of ref document: EP Kind code of ref document: A2 |